Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis

Science Translational Medicine

Volumn 7, Issue 318, 2015, Pages

  Schukur, Lina ^a   Geering, Barbara ^a   Charpin El Hamri, Ghislaine ^b   Fussenegger, Martin ^a,c  

^a ETH ZURICH   (Switzerland)

^b Institut Universitaire de Technologie   (France)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CXCL9 CHEMOKINE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 4; PREDNISOLONE; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 4; TUMOR NECROSIS FACTOR; AMINOQUINOLINE DERIVATIVE; AUTACOID; IL10 PROTEIN, HUMAN; IL4 PROTEIN, HUMAN; IMIQUIMOD; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ACUTE DISEASE; AND GATE LOGIC; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL CELL; BIOSENSOR; CELL ENGINEERING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; FEMALE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMPLANTABLE SYNTHETIC CYTOKINE CONVERTER CELL; INFORMATION SCIENCE; MICROENCAPSULATION; MOUSE; MOUSE MODEL; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL TRANSPLANTATION; CHEMICALLY INDUCED; CHO CELL LINE; CRICETULUS; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSFECTION; GENETICS; HELA CELL LINE; IMMUNOLOGY; LOGIC; METABOLISM; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SIGNAL TRANSDUCTION; SKIN; TIME FACTOR;

AMINOQUINOLINES; ANIMALS; CELL TRANSPLANTATION; CHO CELLS; CRICETULUS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; GENETIC THERAPY; HEK293 CELLS; HELA CELLS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-4; INTERLEUKINS; LOGIC; MICE, INBRED C57BL; PSORIASIS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; SKIN; TIME FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84954290530     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac4964     Document Type: Article

References (50)

1. C. E. M. Griffiths, J. N. W. N. Barker, Pathogenesis and clinical features of psoriasis. Lancet 370, 263-271 (2007).
2. V. M. Yates, G. Watkinson, A. Kelman, Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br. J. Dermatol. 106, 323-330 (1982).
3. P. K. Gregersen, L. M. Olsson, Recent advances in the genetics of autoimmune disease. Annu. Rev. Immunol. 27, 363-391 (2009).
4. D. Margolis, W. Bilker, S. Hennessy, C. Vittorio, J. Santanna, B. Strom, Using an administrative database to assess the risk of malignancy associated with psoriasis. J. Invest. Dermatol. 117, 545 (2001).
5. A. W. Armstrong, C. T. Harskamp, E. J. Armstrong, The association between psoriasis and obesity: A systematic review and meta-analysis of observational studies. Nutr. Diabetes 2, e54 (2012).
6. A. D. Cohen, J. Dreiher, Y. Shapiro, L. Vidavsky, D. A. Vardy, B. Davidovici, J. Meyerovitch, Psoriasis and diabetes: A population-based cross-sectional study. J. Eur. Acad. Dermatol. Venereol. 22, 585-589 (2008).
7. N. N. Mehta, R. S. Azfar, D. B. Shin, A. L. Neimanns, A. B. Troxel, J. M. Gelfand, Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the General Practice Research Database. Eur. Heart J. 31, 1000-1006 (2010).
8. L. C. Tsoi, S. L. Spain, J. Knight, E. Ellinghaus, P. E. Stuart, F. Capon, J. Ding, Y. Li, T. Tejasvi, J. E. Gudjonsson, H. M. Kang, M. H. Allen, R. McManus, G. Novelli, L. Samuelsson, J. Schalkwijk, M. Ståhle, A. D. Burden, C. H. Smith, M. J. Cork, X. Estivill, A. M. Bowcock, G. G. Krueger, W. Weger, J. Worthington, R. Tazi-Ahnini, F. O. Nestle, A. Hayday, P. Hoffmann, J. Winkelmann, C. Wijmenga, C. Langford, S. Edkins, R. Andrews, H. Blackburn, A. Strange, G. Band, R. D. Pearson, D. Vukcevic, C. C. A. Spencer, P. Deloukas, U. Mrowietz, S. Schreiber, S. Weidinger, S. Koks, K. Kingo, T. Esko, A. Metspalu, H. W. Lim, J. J. Voorhees, M. Weichenthal, H. E. Wichmann, V. Chandran, C. F. Rosen, P. Rahman, D. D. Gladman, C. E. M. Griffiths, A. Reis, J. Kere; Collaborative Association Study of Psoriasis (CASP); Genetic Analysis of Psoriasis Consortium; Psoriasis Association Genetics Extension; Wellcome Trust Case Control Consortium 2; R. P. Nair, A. Franke, J. N. W. N. Barker, G. R. Abecasis, J. T. Elder, R. C. Trembath, Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat. Genet. 44, 1341-1348 (2012).
9. L. Fry, B. S. Baker, Triggering psoriasis: The role of infections and medications. Clin. Dermatol. 25, 606-615 (2007).
10. N. V. Valeyev, C. Hundhausen, Y. Umezawa, N. V. Kotov, G. Williams, A. Clop, C. Ainali, C. Ouzounis, S. Tsoka, F. O. Nestle, A systems model for immune cell interactions unravels the mechanism of inflammation in human skin. PLOS Comput. Biol. 6, e1001024 (2010).
11. M. A. Lowes, M. Suárez-Fariñas, J. G. Krueger, Immunology of psoriasis. Annu. Rev. Immunol. 32, 227-255 (2014).
12. A. Michalak-Stoma, J. Bartosińska, M. Kowal, M. Juszkiewicz-Borowiec, A. Gerkowicz, G. Chodorowska, Serum levels of selected Th17 and Th22 cytokines in psoriatic patients. Dis. Markers 35, 625-631 (2013).
13. K. Guilloteau, I. Paris, N. Pedretti, K. Boniface, F. Juchaux, V. Huguier, G. Guillet, F.-X. Bernard, J.-C. Lecron, F. Morel, Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1a, and TNF-α recapitulates some features of psoriasis. J. Immunol. 184, 5263-5270 (2010).
14. S. Eyerich, J. Wagener, V. Wenzel, C. Scarponi, D. Pennino, C. Albanesi, M. Schaller, H. Behrendt, J. Ring, C. B. Schmidt-Weber, A. Cavani, M. Mempel, C. Traidl-Hoffmann, K. Eyerich, IL-22 and TNF-α represent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur. J. Immunol. 41, 1894-1901 (2011).
15. K. Boniface, F.-X. Bernard, M. Garcia, A. L. Gurney, J.-C. Lecron, F. Morel, IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 174, 3695-3702 (2005).
16. S. Kagami, H. L. Rizzo, J. J. Lee, Y. Koguchi, A. Blauvelt, Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol. 130, 1373-1383 (2010).
17. A. Mussi, C. Bonifati, M. Carducci, G. D'Agosto, F. Pimpinelli, D. D'Urso, L. D'Auria, M. Fazio, F. Ameglio, Serum TNF-α levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J. Biol. Regul. Homeost. Agents 11, 115-118 (1997).
18. K. Wolk, E. Witte, E. Wallace, W.-D. Döcke, S. Kunz, K. Asadullah, H.-D. Volk, W. Sterry, R. Sabat, IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: A potential role in psoriasis. Eur. J. Immunol. 36, 1309-1323 (2006).
19. W. Carey, S. Glazer, A. B. Gottlieb, M. Lebwohl, C. Leonardi, A. Menter, K. Papp, A. C. Rundle, D. Toth, Relapse, rebound, and psoriasis adverse events: An advisory group report. J. Am. Acad. Dermatol. 54, S171-S181 (2006).
20. R. Peluso, G. Cafaro, A. Di Minno, S. Iervolino, P. Ambrosino, G. Lupoli, M. N. D. Di Minno, Side effects of TNF-α blockers in patients with psoriatic arthritis: Evidences from literature studies. Clin. Rheumatol. 32, 743-753 (2013).
21. N. Ezra, M. Taban, D. Behroozan, Central serous chorioretinopathy associated with topical corticosteroids in a patient with psoriasis. J. Drugs Dermatol. 10, 918-921 (2011).
22. K. Ghoreschi, P. Thomas, S. Breit, M. Dugas, R. Mailhammer, W. van Eden, R. van der Zee, T. Biedermann, J. Prinz, M. Mack, U. Mrowietz, E. Christophers, D. Schlöndorff, G. Plewig, C. A. Sander, M. Röcken, Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9, 40-46 (2003).
23. K. Asadullah, W.-D. Döcke, M. Ebeling, M. Friedrich, G. Belbe, H. Audring, H.-D. Volk, W. Sterry, Interleukin 10 treatment of psoriasis: Clinical results of a phase 2 trial. Arch. Dermatol. 135, 187-192 (1999).
24. K. Belge, J. Brück, K. Ghoreschi, Advances in treating psoriasis. F1000Prime Rep. 6, 4 (2014).
25. M. E. R. van Meegeren, G. Roosendaal, K. Coeleveld, L. Nieuwenhuizen, S. C. Mastbergen, F. P. J. G. Lafeber, A single intra-articular injection with IL-4 plus IL-10 ameliorates bloodinduced cartilage degeneration in haemophilic mice. Br. J. Haematol. 160, 515-520 (2013).
26. L. van der Fits, S. Mourits, J. S. A. Voerman, M. Kant, L. Boon, J. D. Laman, F. Cornelissen, A.-M. Mus, E. Florencia, E. P. Prens, E. Lubberts, Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182, 5836-5845 (2009).
27. P. Soon-Shiong, Treatment of type I diabetes using encapsulated islets. Adv. Drug Deliv. Rev. 35, 259-270 (1999).
28. D. Jacobs-Tulleneers-Thevissen, M. Chintinne, Z. Ling, P. Gillard, L. Schoonjans, G. Delvaux, B. L. Strand, F. Gorus, B. Keymeulen, D. Pipeleers; Beta Cell Therapy Consortium EU-FP7, Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. Diabetologia 56, 1605-1614 (2013).
29. M. Caskey, F. Lefebvre, A. Filali-Mouhim, M. J. Cameron, J.-P. Goulet, E. K. Haddad, G. Breton, C. Trumpfheller, S. Pollak, I. Shimeliovich, A. Duque-Alarcon, L. Pan, A. Nelkenbaum, A. M. Salazar, S. J. Schlesinger, R. M. Steinman, R. P. Sékaly, Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 208, 2357-2366 (2011).
30. D. Lam, D. Harris, Z. Qin, Inflammatory mediator profiling reveals immune properties of chemotactic gradients and macrophage mediator production inhibition during thioglycollate elicited peritoneal inflammation. Mediators Inflamm. 2013, 931562 (2013).
31. M. Caproni, E. Antiga, L. Melani, W. Volpi, E. Del Bianco, P. Fabbri, Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: A randomizedcontrolled trial. J. Clin. Immunol. 29, 210-214 (2009).
32. M. Gilliet, C. Conrad, M. Geiges, A. Cozzio, W. Thürlimann, G. Burg, F. O. Nestle, R. Dummer, Psoriasis triggered by Toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch. Dermatol. 140, 1490-1495 (2004).
33. T. Mabuchi, T. W. Chang, S. Quinter, S. T. Hwang, Chemokine receptors in the pathogenesis and therapy of psoriasis. J. Dermatol. Sci. 65, 4-11 (2012).
34. M. Pasparakis, I. Haase, F. O. Nestle, Mechanisms regulating skin immunity and inflammation. Nat. Rev. Immunol. 14, 289-301 (2014).
35. H. L. Lu, W. M. Wagner, E. Gad, Y. Yang, H. J. Duan, L. M. Amon, N. Van Denend, E. R. Larson, A. Chang, H. Tufvesson, M. L. Disis, Treatment failure of a TLR-7 agonist occurs due to selfregulation of acute inflammation and can be overcome by IL-10 blockade. J. Immunol. 184, 5360-5367 (2010).
36. D. A. Joyce, D. P. Gibbons, P. Green, J. H. Steer, M. Feldmann, F. M. Brennan, Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur. J. Immunol. 24, 2699-2705 (1994).
37. M. Friedrich, W.-D. Döcke, A. Klein, S. Philipp, H.-D. Volk, W. Sterry, K. Asadullah, Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. J. Invest. Dermatol. 118, 672-677 (2002).
38. P. J. Barnes, Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin. Sci. 94, 557-572 (1998).
39. S. Ausländer, D. Ausländer, M. Müller, M. Wieland, M. Fussenegger, Programmable singlecell mammalian biocomputers. Nature 487, 123-127 (2012).
40. W. C. Ruder, T. Lu, J. J. Collins, Synthetic biology moving into the clinic. Science 333, 1248-1252 (2011).
41. B. Geering, M. Fussenegger, Synthetic immunology: Modulating the human immune system. Trends Biotechnol. 33, 65-79 (2015).
42. C. Kemmer, M. Gitzinger, M. Daoud-El Baba, V. Djonov, J. Stelling, M. Fussenegger, Selfsufficient control of urate homeostasis in mice by a synthetic circuit. Nat. Biotechnol. 28, 355-360 (2010).
43. G. F. Sonnenberg, M. G. Nair, T. J. Kirn, C. Zaph, L. A. Fouser, D. Artis, Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J. Exp. Med. 207, 1293-1305 (2010).
44. R. Kojima, D. Aubel, M. Fussenegger, Novel theranostic agents for next-generation personalized medicine: Small molecules, nanoparticles, and engineered mammalian cells. Curr. Opin. Chem. Biol. 28, 29-38 (2015).
45. D. Berz, E. M. McCormack, E. S. Winer, G. A. Colvin, P. J. Quesenberry, Cryopreservation of hematopoietic stem cells. Am. J. Hematol. 82, 463-472 (2007).
46. E. Santos, J. L. Pedraz, R. M. Hernández, G. Orive, Therapeutic cell encapsulation: Ten steps towards clinical translation. J. Control. Release 170, 1-14 (2013).
47. A. D. Agulnick, D.M.Ambruzs, M.A. Moorman, A. Bhoumik, R. M. Cesario, J. K. Payne, J. R. Kelly, C. Haakmeester, R. Srijemac, A. Z. Wilson, J. Kerr, M. A. Frazier, E. J. Kroon, K. A. D'Amour, Insulin-producing endocrine cells differentiated in vitro from human embryonic stem cells function in macroencapsulation devices in vivo. Stem Cells Transl. Med. 4, 1214-1222 (2015).
48. F. Lienert, J. J. Lohmueller, A. Garg, P. A. Silver, Synthetic biology in mammalian cells: Next generation research tools and therapeutics. Nat. Rev. Mol. Cell Biol. 15, 95-107 (2014).
49. K. Rössger, G. Charpin-El Hamri, M. Fussenegger, Reward-based hypertension control by a synthetic brain-dopamine interface. Proc. Natl. Acad. Sci. U.S.A. 110, 18150-18155 (2013).
50. S. Schlatter, M. Rimann, J. Kelm, M. Fussenegger, SAMY, a novel mammalian reporter gene derived from Bacillus stearothermophilus a-amylase. Gene 282, 19-31 (2002).